Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "Import"

1888 News Found

Solara announces restoration of CEP for ranitidine hydrochloride
News | July 03, 2021

Solara announces restoration of CEP for ranitidine hydrochloride

Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site


Poxel and Sumitomo Dainippon gets TWYMEEG approval
News | June 25, 2021

Poxel and Sumitomo Dainippon gets TWYMEEG approval

The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies


Glenmark receives ANDA approval for inhalation solution
News | June 24, 2021

Glenmark receives ANDA approval for inhalation solution

Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina


Mangalam Drugs commissions intermediate manufacturing facility
News | June 19, 2021

Mangalam Drugs commissions intermediate manufacturing facility

This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent


Govt. to increase Janaushadhi Kendras to 10,000
News | June 15, 2021

Govt. to increase Janaushadhi Kendras to 10,000

Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country


Lupin receives warning letter from U.S. FDA
News | June 14, 2021

Lupin receives warning letter from U.S. FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Lupin launches Digital Asthma Educator platform
News | June 08, 2021

Lupin launches Digital Asthma Educator platform

The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment


Bayer acquires Noria and PSMA Therapeutics
News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)


Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
News | June 03, 2021

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).